LONDON, Feb 12 (Reuters) - Britain's competition body saidon Friday it had fined GlaxoSmithKline 37.6 millionpounds ($54.42 million) for market abuse in striking deals todelay the launch of generic copies of itsantidepressant Seroxat.
GSK said it strongly disagreed and argued its actions hadactually brought down the cost of medicine for the state-runhealth service. The drugmaker added it was considering groundsfor appeal.
Generic drug companies involved were also fined smalleramounts, bringing the total fines to 45 million pounds.
($1 = 0.6909 pounds) (Reporting by Ben Hirschler; editing by Jason Neely)